Although there are several effective treatment options for newly diagnosed Multiple Myeloma (MM), most patients will experience relapse and eventually become refractory to multiple lines of therapy. In recent years, the treatment of MM has changed dramatically because of the approval and subsequent expanded indications of several new agents.
As experts in medication therapy management, pharmacists are uniquely positioned to manage adverse events associated with relapsed/refractory MM therapies. Education on the treatment options for relapsed/refractory multiple myeloma (R/R MM) and how to design optimal therapeutic regimens, including monitoring parameters and appropriate patient counseling, will improve patient outcomes and quality of life.
During this activity, faculty will discuss case scenarios highlighting current challenges with therapy selection, sequencing, and treatment planning for patients with R/R MM; discuss areas of consensus; debate areas of controversy; and elucidate how the latest data fit into the treatment algorithm going forward.
The target audience for this activity includes pharmacists, including clinical and health-system pharmacists, board-certified oncology pharmacists, specialty pharmacy and managed care professionals, and other pharmacists responsible for the care and management of patients with relapsed/refractory multiple myeloma. At the completion of this activity, the participant will be able to:
- Discuss the efficacy and safety data of current and emerging therapeutic regimens for patients with Relapsed/Refractory Multiple Myeloma (R/R MM).
- Given a patient case, design an appropriate therapeutic regimen, including dosing, schedule of administration, and dose modifications for newer classes of agents indicated for R/R MM, with consideration of individual patient and disease characteristics.
- Manage adverse events associated with newer agents and combination regimens in patients with R/R MM therapies.
- Identify key counseling points for patients with R/R MM, including potential risks of therapy and drug-drug interactions with new therapies based on co-morbidities, co-medications, and previous therapies.
Kathryn Maples, PharmD, BCOP
Clinical Pharmacy Specialist, Multiple Myeloma
Winship Cancer Institute, Emory Healthcare
Tim Peterson, PharmD, BCOP
Clinical Pharmacy Specialist – Multiple Myeloma
Memorial Sloan Kettering Cancer Center
New York, New York
Release Date: August 2, 2021
Expiration Date: September 20, 2022
ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-21-168-H01-P has been assigned to this home-study, knowledge-based activity. This activity is approved for 1.25 contact hour (0.125 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Maples has received consulting fees from GlaxoSmithKline, Janssen, Karyopharm, and Sanofi. Dr. Peterson has received consulting fees from GlaxoSmithKline.
This activity is supported by educational grants from Karyopharm Therapeutics, Inc. and Oncopeptides, Inc.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.